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SObjective: The study objective was to compare endobronchial ultrasound-guided transbronchial needle
aspiration (EBUS-TBNA) with mediastinoscopy for mediastinal lymph node staging of potentially resectable
non–small cell lung cancer.
Methods: Patients with confirmed or suspected non–small cell lung cancer who required mediastinoscopy to
determine suitability for lung cancer resection were entered into the trial. All patients underwent EBUS-
TBNA followed by mediastinoscopy under general anesthesia. If both were negative for N2 or N3 disease,
the patient underwent pulmonary resection and mediastinal lymphadenectomy.
Results: Between July 2006 and August 2010, 190 patients were registered in the study, 159 enrolled, and 153
were eligible for analysis. EBUS-TBNAandmediastinoscopy sampled an average of 3 and 4 lymph node stations
per patient, respectively. Themean short axis of the lymph node biopsied byEBUS-TBNAwas 6.9 2.9mm. The
prevalence of N2/N3 disease was 35% (53/153). There was excellent agreement between EBUS-TBNA and me-
diastinoscopy formediastinal staging in 136 patients (91%; Kappa, 0.8; 95% confidence interval, 0.7–0.9). Spec-
ificity and positive predictivevalue for both techniqueswere 100%. The sensitivity, negative predictivevalue, and
diagnostic accuracy formediastinal lymph node staging for EBUS-TBNAandmediastinoscopywere 81%, 91%,
93%, and 79%, 90%, 93%, respectively. No significant differences were found between EBUS-TBNA and me-
diastinoscopy in determining the true pathologicN stage (McNemar’s test,P¼ .78). Therewere no complications
from EBUS-TBNA. Minor complications from mediastinoscopy were observed in 4 patients (2.6%).
Conclusions: EBUS-TBNA andmediastinoscopy achieve similar results for the mediastinal staging of lung can-
cer. As performed in this study, EBUS-TBNA can replace mediastinoscopy in patients with potentially
resectable non–small cell lung cancer. (J Thorac Cardiovasc Surg 2011;142:1393-400)Supplemental material is available online.Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and CarAccurate staging of the disease is mandatory to determine
the prognosis and appropriate treatment. The most signifi-
cant treatment decision lies in the distinction between those
patients who can benefit from surgical resection and those
who should receive chemotherapy and radiation therapy
or both. The existence of metastatic contralateral adenop-
athy (N3) currently contraindicates surgery. Patients with
ipsilateral lymph node metastasis (N2) may be considered
for neoadjuvant therapy followed by surgery on the basis
of studies reporting improved survival with this treatment
approach.2 Therefore, preoperative evaluation of mediasti-
nal lymph nodes is important for selecting the optimal
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Abbreviations and Acronyms
CP-EBUS ¼ convex probe endobronchial
ultrasound
CT ¼ computed tomography
EBUS-TBNA ¼ endobronchial ultrasound-
guided transbronchial needle
aspiration
EUS-FNA ¼ endoscopic ultrasound-guided
fine-needle aspiration
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
ROSE ¼ rapid on-site evaluation
TBNA ¼ transbronchial needle aspiration
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SAt present, the best means to assess lymph node involve-
ment is by direct sampling. The current gold standard
method to obtain such direct sampling is by mediastino-
scopy.3 Mediastinoscopy has the ability to access samples
of the paratracheal lymph node stations (levels 2R, 2L,
4R, 4L), the anterior subcarinal lymph node station (level
7), and the hilar lymph node station (level 10). Mediastino-
scopy is performed under general anesthesia. Complica-
tions related to mediastinoscopy are extremely low when
performed by experienced surgeons.4 Given the invasive
and costly nature of mediastinoscopy, there has been con-
siderable interest recently in the development of techniques
that allow minimally invasive sampling of mediastinal
lymph nodes.
Minimally invasive techniques use needle biopsy to obtain
tissue samples from mediastinal lymph nodes.5,6 Needle
biopsy techniques include transbronchial needle aspiration
(TBNA), transthoracic needle aspiration, endoscopic
ultrasound-guided fine-needle aspiration (EUS-FNA), and,
most recently, endobronchial ultrasound-guided transbron-
chial needle aspiration (EBUS-TBNA).
EBUS-TBNA is a minimally invasive method of medias-
tinal biopsy performed under direct real-time endobron-
chial ultrasound guidance.7-18 EBUS-TBNA allows access
to the paratracheal lymph node stations (levels 2R, 2L,
4R, 4L), the subcarinal lymph node (level 7), and the hilar,
interlobar, and lobar lymph nodes (levels 10, 11, and 12).
Previous studies, including systematic reviews and meta-
analyses, have demonstrated a major impact of EBUS-
TBNA on management of patients with non–small cell
lung cancer (NSCLC), with a diagnostic yield comparable
to mediastinoscopy. However, there have been few compar-
ative studies involving direct comparison of EBUS-TBNA
and the gold standard mediastinoscopy.11 The purpose of
the current study was to compare EBUS-TBNA with
mediastinoscopy for mediastinal lymph node staging of
NSCLC.1394 The Journal of Thoracic and Cardiovascular SurMATERIALS AND METHODS
Study Design
This was a prospective, controlled trial performed in patients with con-
firmed or suspected NSCLC who required a mediastinoscopy as part of
their staging investigations of the mediastinum to determine suitability
for lung cancer resection. This study was approved by the University
Health Network Institutional Research Ethics Board (University Health
Network REB#06-0085-C). A written informed consent was obtained
from all patients. All patients received chest and upper abdominal com-
puted tomography (CT) with contrast injection. CT was used for assess-
ment of resectability of the primary tumor, evaluation of mediastinal
lymph nodes, and exclusion of distant metastases. Lymph nodes with the
short axis larger than 1 cm on chest CTwere classified as positive for ma-
lignancy by CT criteria. Positron emission tomography (PET) was avail-
able for patients who were eligible to undergo PET scan during our
study period (n ¼ 88). Between July 2006 and August 2010, 190 patients
were registered and 153 were eligible for evaluation (Figure 1).
The inclusion and exclusion criteria for the study were as follows:
Inclusion criteria. (1) Patients aged 18 years or older and (2) pa-
tients with confirmed or suspectedNSCLCwho required amediastinoscopy
as part of their staging investigations of the mediastinum to determine suit-
ability for lung cancer resection.
Exclusion criteria. (1) Patients who were deemed on clinical
grounds to be medically unfit for a bronchoscopy or a mediastinoscopy,
(2) patients who had verified stage IV disease or who were not appropriate
for lung cancer resection by virtue of technical inoperability, (3) patients
with known small cell lung cancer, (4) patients with a high clinical suspi-
cion of lymphoma, and (5) patients unable to give informed consent.
After the administration of a general anesthetic, all patients underwent
EBUS-TBNA as detailed below. All patients then underwent standard cer-
vical mediastinoscopy in the same setting. Each patient served as his/her
own control. The surgeon was blinded to the pathologic findings of
EBUS-TBNA. The on-site cytopathologist reported the specimen as ‘‘ade-
quate’’ or ‘‘inadequate’’ for diagnosis. Both EBUS-TBNA and mediastino-
scopy were performed in all patients even if EBUS-TBNA result yielded
N2 or N3 disease. If there was no evidence of N2 or N3 disease on
EBUS-TBNA or mediastinoscopy samples, patients underwent thoracot-
omy, pulmonary resection, and mediastinal lymphadenectomy at the
same setting or at a different time.Endobronchial Ultrasound-Guided Transbronchial
Needle Aspiration
The convex probe endobronchial ultrasound (CP-EBUS) was used to
perform EBUS-TBNA (BF-UC160F-OL8, Olympus, Tokyo, Japan). The
CP-EBUS is integrated with a convex transducer (7.5 MHz) that scans par-
allel to the insertion direction of the bronchoscope. The ultrasound image is
processed in a dedicated ultrasound scanner (EU-C60, Olympus). Static ul-
trasound images were obtained, and the size of lesions were measured in 2
dimensions. Doppler mode imaging was used selectively.
After the induction of general anesthesia, patients were intubated with
an endotracheal tube size 8 or greater or a laryngeal mask airway. Conven-
tional flexible bronchoscopy was first performed, followed by examination
of the mediastinum using the CP-EBUS. The location and size of the lymph
nodes (ipsilateral and contralateral) were characterized and classified as
N1, N2, or N3. A dedicated 22-gauge needle (NA-201SX-4022, Olympus)
was used to perform all EBUS-TBNA procedures as previously de-
scribed.7,8 In brief, a dedicated needle equipped with a protective sheath
was first passed through the working channel of the bronchoscope. After
visualizing the lymph node, the needle was passed out of the sheath,
through the airway, and into the lymph node. After penetration into the
lymph node, the internal stylet was used to clean out the internal lumen
clogged with bronchial membrane or cartilage. The internal stylet was
then removed, and negative pressure was applied with a syringe. Thegery c December 2011
FIGURE 1. Flow chart showing enrollment, allocation, and analysis of
190 patients who were registered in the study, of whom 153 were eligible
for analysis. Thirty-one patients did not enter the study after registration
because of advanced disease (16), decrease in size of lymph node (5),
and patient withdrawal (10). Six patients were excluded after the procedure
because of advanced disease.
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was retrieved and the internal stylet was used once again to push the
specimen out onto a slide for cytologic examination, followed by
a needle rinse in 15 mL of sterile saline. Smears were air dried and fixed
in modified Carnoy’s solution. The air-dried smears were stained with
a modified Field’s stain and evaluated by an on-site cytopathologist to con-
firm ‘‘adequate’’ cell material. Adequate cell material was defined as suf-
ficient material for a specific diagnosis or the presence of lymphocytes on
the specimen. If adequate tissue was not identified by rapid on-site evalu-
ation (ROSE) after 5 passes, the biopsy of that site was terminated. A mod-
ified Papanicolaou stain was used for the Carnoy’s fixed slides. The needle
rinse was processed by cell block or ThinPrep slide production, and light
microscopy was carried out by a cytopathologist (Figure E1).
EBUS-TBNAwas performed by a thoracic surgeon (KY, AP, GD, MDP,
TW, MJ, SK) responsible for the patient. Contralateral lymph nodes were
sampled first followed by midline or ipsilateral lymph nodes. Where mul-
tiple nodes were seen, the most suspicious node in each group was targeted.
Suspicious nodes are defined as round, well demarcated, and echo-poor.
Different needles were used for each lymph node station to prevent
cross-contamination. The localization of the lymph nodes was described
according to the 7th TNM classification for lung cancer.19 EBUS-TBNA
was performed for all lymph nodes greater than 5 mm in CT short-axis
diameter or suspicious lymph nodes on EBUS.
Mediastinoscopy
Standard cervical mediastinoscopy was performed immediately after
EBUS-TBNA by a thoracic surgeon (KY, AP, GD, MDP, TW, MJ, SK)
experienced in the technique. The same surgeon or different surgeons
performed the EBUS-TBNA and mediastinoscopy, but the cytology
results of EBUS-TBNAwere blinded to the surgeon performing the media-
stinoscopy. The paratracheal and subcarinal lymph node stations were sys-
tematically dissected, and lymph nodes from stations 2R, 4R, 2L, 4L, and 7
were evaluated. All stations were investigated, and if lymph nodes were
identified, biopsies were performed irrespective of their size or appearance.
The histologic samples underwent quick section or regular pathologic eval-
uation. Adequate sampling was defined as sufficient material for a specific
diagnosis or presence of lymphoid tissue.The Journal of Thoracic and CarPulmonary Resection
If there was no evidence of N2 or N3 disease on the EBUS-TBNA and
mediastinoscopy samples, patients underwent surgical resection of the tu-
mor at the same setting or a different time. Pulmonary resection and a sys-
tematic nodal dissection were performed in every patient by a thoracotomy
or video-assisted thoracic surgery. The results of the surgical pathology
were subsequently correlated with the results from the EBUS-TBNA and
mediastinoscopy.
Statistical Analysis
Patient demographics and disease characteristics were summarized us-
ing descriptive statistics. Sensitivity, specificity, positive predictive value,
and negative predictive value were calculated. A true negative (N0/N1)
was defined as patients with no N2 or N3 lymph node metastases evaluated
by EBUS-TBNA and mediastinoscopy, and confirmed by surgical-
pathologic examination. Otherwise, the final pathology N stage was taken
as the highest grade among EBUS-TBNA, mediastinoscopy, and surgical N
stage. The agreement between EBUS-TBNA and the gold standard media-
stinoscopy was quantified using Cohen’s Kappa statistics (L) and its 95%
confidence interval (CI). The guideline for interpreting Kappa is greater
than 0.75 as excellent, 0.40 to 0.75 as fair to good, and less than 0.40 as
poor agreement.20 The nonparametric McNemar’s test was also performed
to test whether there were significant differences between the 2 methods in
yielding the correct/incorrect final pathology N stage for each patient in
a paired comparison. All statistical analyses were performed using SAS
(v9.2; SAS Institute Inc, Cary, NC).
RESULTS
Between July 2006 and August 2010, 190 patients were
registered for the study and 159 cases were enrolled
(Figure 1). Thirty-one patients did not proceed after regis-
tration because of advanced disease (16), decrease in lymph
node size on follow-up imaging (5), or patient withdrawal
(10). Six patients were excluded after the procedure because
of advanced disease, leaving 153 available for analysis. The
characteristics of these 153 evaluable patients and the de-
tails of primary lung cancer are shown in Table 1. The ma-
jority of the patients had cN0/1 disease based on imaging
(n ¼ 97, 64%). The mean short axis of the lymph nodes bi-
opsied by EBUS-TBNA was 6.9  2.9 mm. Mediastino-
scopy and EBUS-TBNA were performed by 7 surgeons.
The mean time for EBUS-TBNAwas 20.2  8.1 minutes.
The numbers of mediastinal lymph nodes sampled by
EBUS-TBNA and mediastinoscopy from various lymph
node stations are shown in Table 2. EBUS-TBNA sampled
426 lymph nodes (average 3/patient), and mediastinoscopy
sampled 573 lymph nodes (average 4/patient).
Therewere 8 false-negative lymph node stations onEBUS-
TBNA compared with 14 false-negative lymph node stations
on mediastinoscopy. Inadequate lymph node sampling was
seen in 122 lymph nodes on EBUS-TBNA. Inadequate sam-
plingwasgenerally seenwhenattemptingbiopsyof lymphno-
des less than5mm,andnonewere subsequently shown tohave
metastatic cancer at mediastinoscopy or thoracotomy. Ten
lymph node stations were thought to have inadequate sam-
pling on mediastinoscopy lacking lymphoid tissue (Table 2).
The lymph node staging based on chest CT, EBUS-
TBNA, mediastinoscopy, and final pathology is shown indiovascular Surgery c Volume 142, Number 6 1395
TABLE 1. Patient characteristics
Patient characteristics n ¼ 153
Age, mean (SD), y 66.8 (9.5)
Gender, no. (%)
Male 84 (55)
Female 69 (45)
Histology of lung cancer, no. (%)
Adenocarcinoma 90 (59)
Squamous cell carcinoma 39 (25)
Adenosquamous 2 (1)
Large cell carcinoma 6 (4)
Other types of NSCLC 12 (8)
SCLC 4 (3)
Location of primary tumor, no. (%)
Right upper lobe 60 (39)
Right middle lobe 7 (5)
Right lower lobe 27 (18)
Left upper lobe 34 (22)
Left lower lobe 25 (16)
Clinical stage, no. (%)
IA 47 (31)
IB 26 (17)
IIA 3 (2)
IIB 10 (7)
IIIA 59 (39)
IIIB 5 (3)
IV 3 (2)
Nodal stage by CT or PET, no. (%)
0 90 (59)
1 7 (5)
2 51 (33)
3 5 (3)
Short axis of LN biopsied, mean (SD), mm
All 6.9 (2.9)
2R 6.7 (2.7)
4R 7.0 (2.9)
2L 3.3 (1.2)
4L 5.6 (2.0)
7 8.1 (3.3)
EBUS time, mean (SD), min 20.2 (8.1)
NSCLC, Non–small cell lung cancer; SCLC, small cell lung cancer; CT, computed
tomography; PET, positron emission tomography; LN, lymph node; EBUS, endobron-
chial ultrasound; SD, standard deviation.
TABLE 2. Lymph node stations biopsied by endobronchial ultrasound-
guided transbronchial needle aspiration and mediastinoscopy
LN station Total Malignant Benign Inadequate
LN stations biopsied by EBUS-TBNA
2R 30 12 12 6
4R 137 25 74 (5) 38
2L 2 1 0 1
4L 108 15 39 (1) 54
7 149 25 101 (2) 23
Total 426 78 226 (8) 122
LN stations biopsied by mediastinoscopy
2R 115 16 97 (2) 2
4R 151 26 124 (4) 1
2L 26 1 23 2
4L 132 12 118 (4) 2
7 149 24 122 (4) 3
Total 573 79 484 (14) 10
Number of false-negative LN stations in parentheses. LN, Lymph node; EBUS-TBNA,
endobronchial ultrasound-guided transbronchial needle aspiration.
TABLE 3. Lymph node staging based on different modalities
N Stage CT EBUS-TBNA Mediastinoscopy Final pathology
0 90 (59%) 107 (70%) 109 (71%) 90 (59%)
1 7 (5%) 3 (2%) N/A 10 (7%)
2 51 (33%) 33 (22%) 35 (23%) 42 (27%)
3 5 (3%) 10 (7%) 9 (6%) 11 (7%)
CT, Computed tomography; EBUS-TBNA, endobronchial ultrasound-guided trans-
bronchial needle aspiration.
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(53/153). There was excellent agreement between EBUS-
TBNA and mediastinoscopy for mediastinal staging in
136 patients (91%; Kappa, 0.8; 95% CI, 0.7–0.9). Both
EBUS-TBNA and mediastinoscopy were incorrect in 4
patients. The 4 patients missed by both EBUS-TBNA
and mediastinoscopy had metastases located in station 4R
in 1 patient and station 5 or 6 in 3 patients, which were
out of reach for EBUS-TBNA and mediastinoscopy.
Mediastinoscopy incorrectly staged the mediastinum in 7
patients, and EBUS-TBNA correctly diagnosed these pa-
tients with N2 (n ¼ 5) or N3 (n ¼ 2) disease. On the other
hand, EBUS-TBNA incorrectly staged 6 patients and1396 The Journal of Thoracic and Cardiovascular Surmediastinoscopy correctly staged these patients with N2
(n ¼ 5) or N3 (n ¼ 1) disease. The 6 patients understaged
by EBUS-TBNA included metastases in lymph node
stations not sampled by EBUS-TBNA (station 2R) in 2 pa-
tients and micrometastases in 4 patients (stations 4R, 4L, 7)
(Tables 4 and 5).
The specificity and positive predictive value of both tests
were 100%. The sensitivity, negative predictive value, and
diagnostic accuracy for mediastinal lymph node staging for
EBUS-TBNA and mediastinoscopy were 81%, 91%, 93%,
and 79%, 90%, 93%, respectively. There were no signifi-
cant differences between EBUS-TBNA and mediastino-
scopy in yielding the true pathologic N stage (McNemar’s
test, P ¼ .78) (Table 4).
There were no major complications related to EBUS-
TBNA or mediastinoscopy. Minor complications from
mediastinoscopy were observed in 4 patients (2.6%) (he-
matoma in 2, left recurrent nerve injury in 1, and wound
infection in 1). There were no minor complications related
to EBUS-TBNA.DISCUSSION
The purpose of the present study was to compare the new
minimal invasive modality of EBUS-TBNAwith the estab-
lished gold standard of mediastinoscopy for mediastinal
lymph node staging of NSCLC. As expected, the specificitygery c December 2011
TABLE 4. Agreement in mediastinal lymph node staging between
endobronchial ultrasound-guided transbronchial needle aspiration
and mediastinoscopy
EBUS N stage
Mediastinoscopy
N stage Final N stage No. of cases
Staged correctly by both EBUS and mediastinoscopy
0 or 1 0 or 1 0 or 1 100
2 2 2 28
3 3 3 8
Staged incorrectly
0 or 1 0 or 1 2 4
2 0 2 5
3 2 3 2
0 2 2 5
0 3 3 1
The specificity and positive predictive value of both tests were 100%. The sensitivity,
negative predictive value, and diagnostic accuracy rate of EBUS-TBNA and media-
stinoscopy were 81%, 91%, 93%, and 79%, 90%, 93%, respectively. EBUS, Endo-
bronchial ultrasound.
TABLE 5. Patients with false-negative results of mediastinal staging
Patient
Nodal
station
Diameter of
nodes short/
long axis (mm) Description of case
Staged incorrectly by both EBUS and mediastinoscopy
1 4R 5/10 4R positive on final pathology
2 6 15/18 6 positive on final surgical staging
3 5 5/5 5, 6 positive on final surgical staging
6 10/12
4 5 5/5 5 positive on final surgical staging
Staged incorrectly by EBUS
1 7 3/8 Micrometastasis
2 4L 3/3 Micrometastasis, not sampled by
EBUS
3 2R 3/3 Not sampled by EBUS
4 2R 5/10 N3 lymph node not sampled by EBUS
5 4R 3/8 Micrometastasis
6 7 12/15 Micrometastasis, PET negative
Staged incorrectly by mediastinoscopy
1 4L 12/18 Enlarged and hard node on
mediastinoscopy
2 4L 5/8 Grossly normal on mediastinoscopy
3 4R 15/18 Enlarged node on mediastinoscopy
4 7 5/5 Grossly normal on mediastinoscopy
5 4L 3/5 4R (N2) positive, 4L (N3) negative on
mediastinoscopy
6 7 10/12 Grossly normal on mediastinoscopy
7 4L 3/3 2R, 4R (N2) positive, 4L (N3)
negative on mediastinoscopy
EBUS, Endobronchial ultrasound; PET, positron emission tomography.
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metastatic cancer was identified, were 100%. The sensitiv-
ity, negative predictive value, and diagnostic accuracy for
mediastinal lymph node staging for EBUS-TBNA and me-
diastinoscopy were 81%, 91%, 93%, and 79%, 90%,
93%, respectively. These results demonstrate that these mo-
dalities are comparable in that there were no significant
differences between EBUS-TBNA and mediastinoscopy
in overall ability to determine the true pathologic mediasti-
nal lymph node stage in patients with NSCLC. Both modal-
ities have some limitations, and they are different and in
a sense complementary.
EBUS-TBNA is a minimally invasive method of medias-
tinal biopsy first reported in 2004 with a high diagnostic
yield for the evaluation of mediastinal and hilar lymph no-
des.7 As shown by the growing number of publications,7-18
it is becoming an important modality in the field of
interventional pulmonology and thoracic surgery. The
advantages of EBUS-TBNA include its (1) minimally inva-
sive nature; (2) real-time targeting of lymph nodes; (3) abil-
ity to access hilar, interlobar, and lobar lymph nodes; and
(4) safety. Mediastinoscopy has had a long-standing role
for the definitive pathologic exclusion of N2 or N3 disease.
The current report establishes that EBUS-TBNA can also
accurately distinguish N0/N1 disease from N2 and N3
disease. EBUS-TBNA may also provide the possible detec-
tion of N1 disease.14 This will allow future studies to deter-
mine whether neoadjuvant chemotherapy could improve
survival in subgroups of patients with N1 disease and
poor prognosis.21
Although mediastinoscopy is reported to have an ex-
tremely low complication rate, it requires general anesthe-
sia and may be associated with potentially catastrophic
complications, such as bleeding due to injury of major ves-
sels, tracheobronchial injury, and esophageal trauma.4The Journal of Thoracic and CarMinor complications include left recurrent nerve injury,
pneumothorax, and wound infection. In the present study,
we did not observe major complications related to mediasti-
noscopy. Minor complications from mediastinoscopy were
observed in 4 patients (2.6%) (hematoma in 2, transient left
recurrent nerve injury in 1, and wound infection in 1). There
were no complications related to EBUS-TBNA in the
present study.
The majority of the patients in the present study had clin-
ical N0 disease on chest CT or PET scan (n ¼ 90, 59%),
with a normal mediastinum by CT imaging criteria. This
contributes to the sensitivity of 81% in assessing the medi-
astinum by EBUS-TBNA, because sensitivity is related to
the underlying prevalence of N2/N3 disease. Sensitivity in
this study is lower than previously reported (85%–
96%),7-18 where EBUS-TBNAwas evaluated in the setting
of patients with enlarged nodes on CT scan. Although
EBUS-TBNA is capable of sampling subcentimeter lymph
nodes, there is a limit in sampling very small lymph nodes
as shown by the number of inadequate samples in the small
sized lymph nodes in the EBUS-TBNA group. We did note
that the majority of instances of inadequate sampling by
EBUS-TBNAwere in lymph nodes less than 5 mm in short
axis. It is important to note that none of these inadequate
samplings had metastases on final pathology. In ourdiovascular Surgery c Volume 142, Number 6 1397
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less than 5 mm is probably the limit to a good biopsy
with the EBUS-TBNA scope and a 22-gauge needle. Sam-
pling errors will always occur in small lymph nodes, which
raises the question, do we really need to sample the medias-
tinum in patients with clinical N0 disease lung cancer with
such small lymph nodes? The answer still needs to be fur-
ther investigated.22
Accurate staging remains essential for management of
patients with lung cancer. Perhaps the most important issue
is the determination of patients who are eligible for curative
surgical resection. With the introduction of new modalities,
a key issue has been how to incorporate these modalities,
such as EBUS-TBNA or EUS-FNA, into the algorithm for
lung cancer staging.6,7 In a recent randomized controlled
multicenter trial, a combination of EBUS-TBNA and
EUS-FNA followed by mediastinoscopy compared with
mediastinoscopy alone resulted in greater sensitivity
(from 85% to 94%) for mediastinal lymph node metastases
and fewer unnecessary thoracotomies.23 Our current study
did not incorporate EUS-FNA for minimally invasive stag-
ing before mediastinoscopy, because the main objectivewas
a direct comparison between 2 procedures (EBUS-TBNA
and mediastinoscopy) that have access to the same lymph
node stations.
Our current study showed excellent performance of both
EBUS-TBNA and mediastinoscopy for identifying patients
with negative mediastinal disease with a negative predictive
value of 91% and 90%, respectively. The important ques-
tion is whether one should perform a mediastinoscopy after
a negative EBUS-TBNA in potentially resectable lung
cancer. The combined sensitivity and negative predictive
value of EBUS-TBNA and mediastinoscopy in our current
setting were 92% and 96%, respectively. This is only a 5%
increase of the negative predictive value for mediastinal
staging. In a setting with a low prevalence of mediastinal
disease, mediastinoscopy may not add significant advan-
tages after a negative EBUS and may not justify the extra
costs.
Study Limitations
Some limitations apply to this study. Because of the study
design, EBUS-TBNA was performed under general anes-
thesia through an endotracheal tube in the majority of cases.
This might contribute to the high diagnostic yield in this
study compared with awake patients. However, stations
2R and 2L were sometimes difficult to assess because of
the presence of the endotracheal tube. The number of sam-
pled lymph nodes at station 2R (EBUS-TBNA 30 nodes vs
mediastinoscopy 115 nodes) and 2L (EBUS-TBNA 2 nodes
vs mediastinoscopy 26 nodes) indicates the superiority of
mediastinoscopy for sampling stations 2R and 2L in our
current study protocol. However, we have noted that the
use of laryngeal mask airway obviates the limitation1398 The Journal of Thoracic and Cardiovascular Surimposed by the endotracheal tubes, and we have moved to
this form of intubation when performing EBUS-TBNA in
an anesthetized patient. This modification might further
secure the role of EBUS-TBNA over mediastinoscopy,
because 2 of 6 patients in whom EBUS was negative and
mediastinoscopy was positive had metastatic disease in
station 2.
Second, a cytopathologist was always present for ROSE
for EBUS-TBNA. ROSE has been shown to reduce the
number of TBNA necessary for a firm diagnosis.24 Because
not all centers have the resources to perform ROSE, the re-
sults may not be generalizable to all settings. However, in
case of EBUS-TBNA, if one performs 3 passes with the nee-
dle for biopsy, theremay not be significant differences in the
accuracy when performed without ROSE.12 Real-time
imaging of lymph nodes also allows assessment of lymph
node morphology that provides an indication of whether
a node is normal or not.15
Third, EBUS-TBNA was performed by general thoracic
surgeons with extensive familiarity with mediastinal anat-
omy and correlation with radiologic findings. Thus, the
excellent results obtained may not be generalizable to all
studies of EBUS-TBNA. Nonetheless, this study clearly
delineates what can be achieved with this minimally inva-
sive technique under optimal conditions.
Finally, preoperative staging before EBUS-TBNA and
mediastinoscopy was mainly based on CT findings, because
PET scanning was not available for all patients at the start of
the study. CT scanning of the chest is useful in providing
anatomic detail, but the accuracy of CT in differentiating
benign from malignant lymph nodes in the mediastinum
is poor (sensitivity, 51%; 95% CI, 47–54; specificity,
85%; 95% CI, 84–88). PET scanning has improved sensi-
tivity and specificity over CT for staging the mediastinum
(sensitivity, 74%; 95% CI, 69–79; specificity, 85%; 95%
CI, range 82–88).25 By combining CTand PET for noninva-
sive mediastinal lymph node staging, clinical staging would
have been altered in our study; however, this does not de-
tract from our primary conclusion that in a head-to-head
comparison of EBUS-TBNA and mediastinoscopy, both
techniques had equivalent accuracy in the mediastinal
staging of lung cancer.
CONCLUSIONS
There were no significant differences between EBUS-
TBNA and mediastinoscopy in determining the true
pathologic mediastinal lymph node stage in patients with
potentially operable lung cancer. These findings have major
implications for patients undergoing preoperative staging
for lung cancer. Our results show that EBUS-TBNA,
when performed as in this study, can replace mediastino-
scopy for accurate staging of the mediastinum in potentially
resectable lung cancer. Furthermore, EBUS-TBNA avoids
an incision, is more comfortable for the patient, and enablesgery c December 2011
Yasufuku et al General Thoracic Surgerymediastinal reassessment. The potential for repeat sampling
with relative ease is also possible with EBUS-TBNA,
because redo EBUS-TBNA is simpler and safer than redo
mediastinoscopy.13 Future studies will be needed to evalu-
ate the role of EBUS-TBNA and mediastinoscopy after in-
duction treatment.
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Dr Joel Cooper (Philadelphia, Pa). I have no disclosures other
than great pride in one of my former institutions, the University of
Toronto.
Dr Yasufuku, congratulations on your membership this morning
to the American Association of Thoracic Surgery. I appreciate the
article, which I had a chance to review 1 week in advance, which
was outstanding.
I am convinced from the article and your presentation that you
have demonstrated equivalent ability to stage the mediastinum
with EBUS and mediastinoscopy. It was a well-designed and
very well-executed study, and the key features you pointed out
were well-trained thoracic surgeons who understand their anat-
omy, the use of general anesthesia in this particular series, and
outstanding cytopathology.
I have several questions I will ask one at a time. Are the results
you have presented regarding the correlation between EBUS and
mediastinoscopy based on the on-site sampling or were there cases
where the cell block and later final pathology changed the results?
If you achieved these results with on-site sampling, I want to know
how you did it, because we certainly cannot produce this degree of
accuracy with on our on-site diagnoses.
Dr Yasufuku. In terms of on-site cytology, we have compared
the results of on-site cytologic findings with the final findings from
the cell block, and in our 153 patients, there was no discrepancy
between the diagnosis of the ROSE cytology and the final cytol-
ogy. I may not have been clear, but for this study, some patients
went directly to resection after the mediastinoscopy and EBUS
and then some patients had their resection done a few days later.
In case the patient went directly to resection, the decision was
based on our findings on ROSE cytology and quick section from
lymph nodes sampled by mediastinoscopy.
It is an important issue about whether we can rely on the results
of ROSE cytology, and more important to be able to collaborate
with your cytopathologists. In our experience, we have learneddiovascular Surgery c Volume 142, Number 6 1399
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Sa lot by doing this study, because we get direct feedback from the
cytopathologist, and by doing that, we have been able to modify
how we sample our lymph nodes so that we can submit a better
sample.
Dr Cooper. Clearly, the significance that a person attaches to
the presence or absence of mediastinal lymph node involvement
will determine how vigorously he or she attempts to pursue the
goal that you achieved. What is your current policy on patients
with known or suspected lung cancer? How important is it to
you to obtain accurate mediastinal node sampling before thoracot-
omy, and what do you do with that information?
Dr Yasufuku. I think accurate mediastinal lymph node staging
is an important issue that affects patient outcome. In our current
practice, according to the results of our study, when patients
have a clinical N2 disease based on imaging, we would start out
the invasive staging with endobronchial ultrasound. We not only
sample 1 lymph node station, but, as I showed in this study, we typ-
ically do systematic lymph node sampling, not just going after
1 lymph node. Even if we do find metastasis in 1 lymph node,
we would also check the other mediastinal lymph node stations.
If we do confirm the disease and it is resectable, we would have
the patient undergo induction treatment. I think the beauty about
EBUS is that a redo EBUS is typically easier than a redo mediasti-
noscopy. So we can go back after induction treatment, follow-up
on these patients, and actually safely restage the patients. If neces-
sary, we can always do a mediastinoscopy as well.
Dr Cooper. Thank you, and that answered another question that
I had. Finally, do you obtain sufficient material for tumor markers,
which increasingly is important in directing the neoadjuvant
therapy of these patients?
Dr Yasufuku. Sometimes it may be a challenge, but if done in
the correct way, we have been able to obtain adequate samples for
molecular analysis, such as epidermal growth factor receptor mu-
tation analysis. Regular immunohistochemistry is done routinely
by the cytopathologist using the cell block, and the cytopathologist
is typically happy with what we submit.COMMEN
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1400 The Journal of Thoracic and Cardiovascular SurDr Frank Detterbeck (New Haven, Conn). Just a quick com-
ment. I think that EBUS is not EBUS is not EBUS, and mediasti-
noscopy is not mediastinoscopy. Certainly EBUS as you have done
it is different from what many people do; they quickly aspirate 1
node station and that is it, and the same with mediastinoscopy,
as Alex Little showed us in the United States in 2005, where
50% don’t even sample a single node. You have done a very sys-
tematic staging. Furthermore, video mediastinoscopy is better
than old-fashioned mediastinoscopy. It is important for us to con-
sider these results in this context as we figure out how to imple-
ment them more broadly.
Dr Bryan Meyers (St Louis, Mo). I enjoyed your article. It is
going to be an excellent contribution to the literature. The only
area where either of your treatment arms diverged from standard
clinical care was the use of a different needle at each site. Equip-
ment from Olympus was donated for the trial, and so it was okay.
We don’t have that same advantage during a case of routine clin-
ical care. How do you think that discrepancymight affect the inter-
pretation or generalizability of your results, and could you justify
why you chose to do that?
Dr Yasufuku. Thank you for raising an important issue. The
reason why we chose to use different needles was because we
wanted to eliminate contamination. I think we should ideally use
different needles for different lymph node stations, especially
when you do not have ROSE cytology where the cytopathologists
can tell you if the needle you used was positive for cancer or not.
We always start out our sampling from the N3 nodes and then work
our way to the N2 and N1 nodes. Needles cost approximately $80
to $100 each, but to prevent contamination and possible upstaging,
I think it is important to use different needles.
If you have ROSE cytologic evaluation and the lymph nodes
are found to be negative for malignancy, it may be possible to
use the same needle after washing the needle properly; however,
there have been no studies looking at the use of the same needle
for different lymph node stations and the impact on the final
diagnosis.TARYMediastinoscopy: An obsolete procedure?Valerie W. Rusch, MDFor approximately 50 years, mediastinoscopy has been
a pivotal part of the pretreatment staging of lung cancer.1
At one time, respected thoracic surgical groups in North
America and Europe considered mediastinoscopy manda-
tory before proceeding to resection of a non–small cell
lung cancer (NSCLC). However, during the past 30 years,
improvements in noninvasive imagingmodalities, first com-
puted tomography and then positron emission tomography,gery c December 2011
FIGUREE1. A, CT scan demonstrates enlargement of lymph node 4L in 68-year-old patient with lung cancer of the left lower lobe. B, EBUS images with
the Doppler mode show 4L (LN) between the aorta and the pulmonary artery. Cytologic and pathologic results demonstrate adenocarcinoma (C, D).
AO, Aorta; PA, pulmonary artery; LN, lymph node.
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